BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Drug Discovery

Innovent’s IBI363 Secures Second FDA Fast Track Designation for Advanced Lung Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...

February 17, 2025 | News

Akeso Receives IND Approval in China for AK139, the First IL-4Rα/ST2 Bispecific Antibody

Akeso, Inc. is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (...

February 14, 2025 | News

XPOVIO® Secures Approval in Taiwan as First XPO1 Inhibitor for Relapsed/Refractory Multiple Myeloma

XPOVIO® is the first XPO1 inhibitor approved in Taiwan for the treatment of adult patients with relapsed/refractory multiple...

February 14, 2025 | News

Australia's Telix Pharmaceuticals Secures MHRA Approval for Illuccix® Prostate Cancer Imaging Agent in the UK

Telix Pharmaceuticals Limited announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approve...

February 13, 2025 | News

Taiwan's Caliway Biopharmaceuticals Reports Groundbreaking Results for CBL-514 in U.S. and Canada Phase 2b Study

Caliway Biopharmaceuticals unveiled the impressive results of its second Phase 2b clinical study (CBL-0205) for CBL-514, the world’s first in...

February 11, 2025 | News

Fresenius Kabi Launches Calcitonin Salmon Injection to Treat Bone Disorders and Hypercalcemia

Fresenius Kabi, an operating company of Fresenius, announced it has introduced Calcitonin Salmon Injection, USP Synthetic, a calcium regulator, for the tre...

February 11, 2025 | News

Pfizer and Astellas Announce Sustained Survival Benefit in Advanced Urothelial Cancer with PADCEV® and KEYTRUDA® Combination

Enfortumab vedotin plus pembrolizumab continues to demonstrate superior efficacy versus chemotherapy in a broad population, reinforcing the combination a...

February 11, 2025 | News

LG AI Research Partners with Seoul National University to Advance Protein Multistate Prediction AI

LG AI Research signed a joint research agreement at the Global Lounge of LG Science Park in Magok, Gangseo-gu, Seoul, with Prof. Min-Kyung Baek&n...

February 10, 2025 | News

Keymed Biosciences Gains NMPA Approval for Stapokibart in Treating Seasonal Allergic Rhinitis

Keymed Biosciences announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug A...

February 10, 2025 | News

Nuance Pharma Secures First Regulatory Approval for Ohtuvayre™ in Macau for COPD Treatment

Nuance Pharma ("Nuance") announced that the Pharmaceutical Administration Bureau Macau approved Ohtuvayre™ (ensifentrine) for the maintenance tr...

February 07, 2025 | News

Harbour BioMed Secures NMPA Approval for HBM9378/SKB378 and Signs $970M Global Licensing Deal

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel anti...

February 06, 2025 | News

Argent BioPharma’s CannEpil® Offers New Hope for Drug-Resistant Epilepsy Patients

Argent BioPharma Limited (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company, is pioneering a transformative approach to drug-resistant e...

February 06, 2025 | News

Akeso Completes Global Phase III Enrollment for Ivonescimab in Squamous NSCLC

Akeso, Inc. is excited to announce the completion of patient enrollment in the global Phase III clinical trial (HARMONi-6/AK112-306) evaluating ivonescimab...

February 06, 2025 | News

Daiichi Sankyo & AstraZeneca’s Datopotamab Deruxtecan Recommended for EU Approval After Cutting Disease Progression Risk by 37%

Recommendation based on TROPION-Breast01 results showing Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan reduced risk of disease prog...

February 03, 2025 | News

Stay Connected